Benestermycin vet. Spenalyf, smyrsli Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

benestermycin vet. spenalyf, smyrsli

boehringer ingelheim vetmedica gmbh* - framycetinum súlfat; benethaminum penicillinum inn; penethamate hydroiodide ban - spenalyf, smyrsli

Geepenil Vet. Stungulyfsstofn og leysir, lausn 24 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

geepenil vet. stungulyfsstofn og leysir, lausn 24 g

orion corporation - benzylpenicillinum natríum - stungulyfsstofn og leysir, lausn - 24 g

Azithromycin STADA Filmuhúðuð tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

azithromycin stada filmuhúðuð tafla 500 mg

stada arzneimittel ag - azithromycinum mónóhýdrat - filmuhúðuð tafla - 500 mg

Azithromycin STADA Mixtúruduft, dreifa 40 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

azithromycin stada mixtúruduft, dreifa 40 mg/ml

stada arzneimittel ag - azithromycinum díhýdrat - mixtúruduft, dreifa - 40 mg/ml

Azitromicina Normon Filmuhúðuð tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

azitromicina normon filmuhúðuð tafla 500 mg

laboratorios normon s.a. - azithromycinum díhýdrat - filmuhúðuð tafla - 500 mg

Zitromax Filmuhúðuð tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zitromax filmuhúðuð tafla 500 mg

pfizer aps - azithromycinum díhýdrat - filmuhúðuð tafla - 500 mg

Zitromax Mixtúruduft, dreifa 40 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zitromax mixtúruduft, dreifa 40 mg/ml

pfizer aps - azithromycinum díhýdrat - mixtúruduft, dreifa - 40 mg/ml

Zitromax Stofn fyrir innrennslisþykkni, lausn 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zitromax stofn fyrir innrennslisþykkni, lausn 500 mg

pfizer aps - azithromycinum díhýdrat - stofn fyrir innrennslisþykkni, lausn - 500 mg

Olumiant Evrópusambandið - íslenska - EMA (European Medicines Agency)

olumiant

eli lilly nederland b.v. - baricitinib - liðagigt, liðagigt - Ónæmisbælandi lyf - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant má nota sem einlyfjameðferð eða í samsettri meðferð með metotrexati. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Afstyla Evrópusambandið - íslenska - EMA (European Medicines Agency)

afstyla

csl behring gmbh - lonoctocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan storkuþætti viii skortur). afstyla getur verið notað fyrir öllum aldri tekur.